Next Article in Journal
Multiparametric Magnetic Resonance Imaging-Ultrasound Fusion Transperineal Prostate Biopsy: Diagnostic Accuracy from a Single Center Retrospective Study
Next Article in Special Issue
Multimodality Treatment including Surgery Related to the Type of N2 Involvement in Locally Advanced Non-Small Cell Lung Cancer
Previous Article in Journal
Profiling Cisplatin Resistance in Head and Neck Cancer: A Critical Role of the VRAC Ion Channel for Chemoresistance
Previous Article in Special Issue
Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung Cancer
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Primary Lung Cancer Organoids for Personalized Medicine—Are They Ready for Clinical Use?

by
Raphael S. Werner
,
Michaela B. Kirschner
and
Isabelle Opitz
*
Department of Thoracic Surgery, University Hospital Zurich, 8091 Zurich, Switzerland
*
Author to whom correspondence should be addressed.
Equal contribution.
Cancers 2021, 13(19), 4832; https://doi.org/10.3390/cancers13194832
Submission received: 23 August 2021 / Revised: 22 September 2021 / Accepted: 23 September 2021 / Published: 28 September 2021

Simple Summary

Identification of novel therapeutic strategies for the treatment of non-small cell lung cancer (NSCLC) remains an urgent need in the area of lung cancer research. Traditional in vitro cell culture systems form one of the corner stones of cancer research. However, the growth of cancer cells in a two-dimensional pattern on a plastic dish in artificial conditions is not ideal, as the growth pattern significantly differs from that of a complex tumor in a patient. Hence, in recent years, efforts have been undertaken to generate more complex three-dimensional in vitro models, so-called organoid or tumoroid models, that more closely resemble the growth pattern and tumor heterogeneity observed in a patient. In this review, we summarize the efforts thus far undertaken in the area of NSCLC organoid development.

Abstract

Despite many developments in recent years, non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death worldwide. Therefore, additional research, aiming to further elucidate the underlying molecular mechanisms of malignant transformation and development of therapy resistance, as well as the identification of additional novel therapeutic avenues, is crucial. For this purpose, reliable in vitro models are indispensable, as they allow for quick identification of suspected oncogenic drivers or evaluation of novel therapeutic strategies in a timely and cost-effective fashion. However, standard two-dimensional cell culture systems, the most frequently used in vitro model, are usually not truly representative of the situation in a patient as these models lack the tumor heterogeneity, the surrounding tumor microenvironment and the three-dimensional complexity of a tumor in vitro. For this reason, 3D cell culture systems, in particular organoids generated from normal non-malignant cells or tumor cell-based organoids (tumoroids), have in recent years gained much attention as alternative in vitro model systems that more closely resemble the actual primary tumor. In this review, we provide an overview of the available literature in the field of NSCLC organoids, which might still be in its infancy, but is gaining momentum.
Keywords: non-small cell lung cancer; organoids; tumoroids; cancer model; personalized medicine non-small cell lung cancer; organoids; tumoroids; cancer model; personalized medicine

Share and Cite

MDPI and ACS Style

Werner, R.S.; Kirschner, M.B.; Opitz, I. Primary Lung Cancer Organoids for Personalized Medicine—Are They Ready for Clinical Use? Cancers 2021, 13, 4832. https://doi.org/10.3390/cancers13194832

AMA Style

Werner RS, Kirschner MB, Opitz I. Primary Lung Cancer Organoids for Personalized Medicine—Are They Ready for Clinical Use? Cancers. 2021; 13(19):4832. https://doi.org/10.3390/cancers13194832

Chicago/Turabian Style

Werner, Raphael S., Michaela B. Kirschner, and Isabelle Opitz. 2021. "Primary Lung Cancer Organoids for Personalized Medicine—Are They Ready for Clinical Use?" Cancers 13, no. 19: 4832. https://doi.org/10.3390/cancers13194832

APA Style

Werner, R. S., Kirschner, M. B., & Opitz, I. (2021). Primary Lung Cancer Organoids for Personalized Medicine—Are They Ready for Clinical Use? Cancers, 13(19), 4832. https://doi.org/10.3390/cancers13194832

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop